The effect of COVID-19 vaccination on anticoagulation stability in adolescents and young adults using vitamin K antagonists

The European Medicine Agency has authorized COVID-19 vaccination in adolescents and young adults (AYAs) from 12  years onwards. In elderly vitamin K antagonist (VKA) users, COVID-19 vaccination has been associated with an increased risk of supra- and subtherapeutic INRs. Whether this association is also observed in AYAs using VKA is unknown. Our aim was to describe the stability of anticoagulation after COV ID-19 vaccination in AYA VKA users.

Source: Thrombosis Research - June 11, 2023 Category: Hematology Authors: Chantal Visser, Arjen Yousefi, Melchior C. Nierman, Menno V. Huisman, Anouk J.W. Gulpen, C. Heleen van Ommen, Marieke J.H.A. Kruip, Dutch COVID and Thrombosis Coalition Tags: Full Length Article Source Type: research